| dc.creator |
TÜRKMENOĞLU, BURÇİN |
|
| dc.creator |
Bayar, Irem |
|
| dc.creator |
AKKOÇ, Senem |
|
| dc.date |
2024-07-01T00:00:00Z |
|
| dc.date.accessioned |
2025-02-25T10:20:07Z |
|
| dc.date.available |
2025-02-25T10:20:07Z |
|
| dc.identifier |
39f13148-7df9-476d-bc5f-fe3b6a52dc0b |
|
| dc.identifier |
10.1007/s42250-024-00893-7 |
|
| dc.identifier |
https://avesis.sdu.edu.tr/publication/details/39f13148-7df9-476d-bc5f-fe3b6a52dc0b/oai |
|
| dc.identifier.uri |
http://acikerisim.sdu.edu.tr/xmlui/handle/123456789/99365 |
|
| dc.description |
Two 1,2-disubstituted benzimidazole-based compounds (2 and 3) were synthesized in this study. The antiproliferative activities of these compounds 1-(4-methylbenzyl)-2-p-tolyl-1H-benzo[d]imidazole (2), 1-(3-methoxybenzyl)-2-p-tolyl-1H-benzo[d]imidazole (3) together with cisplatin as a positive control drug were performed by the MTT method against the MDA-MB-231 breast cancer cell line. Compound 2 exhibited relatively higher cytotoxic activity. Molecular docking studies of compounds were performed against five breast cancer targets (PARP5A, PARP1, Bcl-2, JAK2, CDK4). By interacting with these targets, effective amino acid residues and binding parameter values in the binding site were determined. |
|
| dc.language |
eng |
|
| dc.rights |
info:eu-repo/semantics/closedAccess |
|
| dc.title |
Biological and in Silico Studies on the Benzimidazole-Based Compounds |
|
| dc.type |
info:eu-repo/semantics/article |
|